AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Chairman’s report (verbal update)
5. Minutes of previous meeting
6. Appraisal 1:
   Paclitaxel albumin (Abraxane®)
   For the treatment of metastatic breast cancer
   1/AWMSG/0410
7. Appraisal 2:
   Bortezomib (Velcade®)
   For first-line treatment of multiple myeloma
   2/AWMSG/0410
8. Appraisal 3:
   Pramipexole prolonged release tablets (Mirapexin®)
   For idiopathic Parkinson’s disease
   3/AWMSG/0410
9. Appraisal 4:
   Enoxaparin (Clexane®)
   For the treatment of acute ST-segment elevation myocardial infarction (STEMI)
   4/AWMSG/0410
10. Appraisal 5:
    Fentanyl (Instanyl®)
    For breakthrough cancer pain
    5/AWMSG/0410
11. Appraisal 6:
    Epoetin-ζ (zeta) (Retacrit®)
    For the treatment of anaemia of renal origin and chemotherapy
    6/AWMSG/0410
12. Update on AWMSG’s Medicines Strategy for Wales
    7/AWMSG/0410

Date of next meeting – Wednesday 23rd June 2010
at The Angel Hotel, Abergavenny

Enclosure

1/AWMSG/0410
2/AWMSG/0410
3/AWMSG/0410
4/AWMSG/0410
5/AWMSG/0410
6/AWMSG/0410
7/AWMSG/0410
8/AWMSG/0410